178 related articles for article (PubMed ID: 35298613)
1. The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia.
Kumar R; Pereira RS; Niemann J; Azimpour AI; Zanetti C; Karantanou C; Minka W; Minciacchi VR; Kowarz E; Meister M; Godavarthy PS; Maguer-Satta V; Lefort S; Wiercinska E; Bonig H; Marschalek R; Krause DS
Blood Adv; 2022 Jun; 6(12):3611-3624. PubMed ID: 35298613
[TBL] [Abstract][Full Text] [Related]
2. The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
Hoang VT; Verma D; Godavarthy PS; Llavona P; Steiner M; Gerlach K; Michels BE; Bohnenberger H; Wachter A; Oellerich T; Müller-Kuller U; Weissenberger E; Voutsinas JM; Oehler VG; Farin HF; Zörnig M; Krause DS
Leukemia; 2019 Jul; 33(7):1700-1712. PubMed ID: 30635626
[TBL] [Abstract][Full Text] [Related]
3. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.
Behrens YL; Schienke A; Davenport C; Lentes J; Tauscher M; Steinemann D; Rasche M; Knirsch S; Joachim S; Reinhardt D; Schlegelberger B; Göhring G
Cancer Genet; 2021 Jun; 254-255():70-74. PubMed ID: 33647814
[TBL] [Abstract][Full Text] [Related]
5. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
6. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
[TBL] [Abstract][Full Text] [Related]
7. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.
Krause DS; Lazarides K; von Andrian UH; Van Etten RA
Nat Med; 2006 Oct; 12(10):1175-80. PubMed ID: 16998483
[TBL] [Abstract][Full Text] [Related]
8. The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
Mizukawa B; O'Brien E; Moreira DC; Wunderlich M; Hochstetler CL; Duan X; Liu W; Orr E; Grimes HL; Mulloy JC; Zheng Y
Blood; 2017 Sep; 130(11):1336-1346. PubMed ID: 28778865
[TBL] [Abstract][Full Text] [Related]
9. The Flot2 component of the lipid raft changes localization during neural differentiation of P19C6 cells.
Hanafusa K; Hayashi N
BMC Mol Cell Biol; 2019 Aug; 20(1):38. PubMed ID: 31455216
[TBL] [Abstract][Full Text] [Related]
10. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
11. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Exp Hematol; 1999 Sep; 27(9):1384-96. PubMed ID: 10480429
[TBL] [Abstract][Full Text] [Related]
12. Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice.
Pelletier SD; Hong DS; Hu Y; Liu Y; Li S
Blood; 2004 Oct; 104(7):2163-71. PubMed ID: 15213099
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
Antoszewska-Smith J; Pawlowska E; Blasiak J
Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
[TBL] [Abstract][Full Text] [Related]
14. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
Naka K; Hoshii T; Muraguchi T; Tadokoro Y; Ooshio T; Kondo Y; Nakao S; Motoyama N; Hirao A
Nature; 2010 Feb; 463(7281):676-80. PubMed ID: 20130650
[TBL] [Abstract][Full Text] [Related]
16. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria.
Kaddu S; Zenahlik P; Beham-Schmid C; Kerl H; Cerroni L
J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):966-78. PubMed ID: 10365929
[TBL] [Abstract][Full Text] [Related]
17. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia.
Uhm KO; Lee ES; Lee YM; Park JS; Kim SJ; Kim BS; Kim HS; Park SH
J Korean Med Sci; 2009 Jun; 24(3):493-7. PubMed ID: 19543515
[TBL] [Abstract][Full Text] [Related]
18. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia.
Fattizzo B; Radice T; Cattaneo D; Pomati M; Barcellini W; Iurlo A
Clin Lab; 2014; 60(11):1929-32. PubMed ID: 25648037
[TBL] [Abstract][Full Text] [Related]
19. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
20. FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NFκB pathway.
Liu X; Mai H; Jiang H; Xing Z; Peng D; Kong Y; Zhu C; Chen Y
BMC Cancer; 2019 Jul; 19(1):679. PubMed ID: 31291942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
